GSK Promoting Collaboration Through Radical Openness
Case Code: BSTR484 Case Length: 18 Pages Period: 2001-2015 Pub Date: 2015 Teaching Note: Not Available |
Price: Rs.600 Organization: GlaxoSmithKline plc. Industry: Pharmaceutical Countries: US Themes: Radical Openness |
Abstract Case Intro 1 Case Intro 2 Excerpts
Abstract
GlaxoSmithKline plc (GSK) is redefining the way pharmaceutical industry works. In an industry which is known for secrecy and non-transparency, GSK has taken to radically defining openness by adapting open innovation and opening its labs for collaborations. It is also sharing its clinical trials data and intellectual property in order to promote transparency and is hoping to discover drugs faster and save millions of people suffering from various diseases. On the other critics opined that this open strategy is a part of market segmentation strategy to cater to patients in both the developing countries and the developed countries. They say that there is no major difference to patients on the ground as the price of GSK's products were still out of the pocket of millions residing in least developed countries.
While the critics doubt the seriousness of GSK’s radical openness, the company hopes that its efforts would bring about a change in a long run and set new benchmarks in the pharmaceutical industry.
Issues
The case is structured to achieve the following teaching objectives:
- Identify the driving forces behind radical Openness
- Understand the role played by Radical Openness in a secretive pharmaceutical industry
- Identify the quantum of benefits that GSK realized as a result of Radical Openness
- Debate on Radical Openness as a competitive Advantage
Contents
-
Tough Time for Andrew Witty, CEO of GSK
Overview of Pharmaceutical Industry
Growth Drivers
Challenges
About GSK
Radical Openness @ GSK
The Criticism
The Outcomes
Next Level of Openness
Exhibits
Keywords
Radical Openness, Pharmaceutical industry, GSK, Transparency, Open Lab, Clinical trials, Intellectual property, Research and Development, Clinical Study Register, Harvard Medical School, Non-Communicable Diseases, HIV, Malaria, Cancer, Neglected Tropical Diseases
Buy this case study (Please select any one of the payment options)
Price: Rs.600 |
Price: Rs.600 | PayPal (13 USD) |